EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognosis of pediatric‐onset inflammatory bowel disease associated with primary sclerosing cholangitis: A population‐based study

Marie-Laura Godet iD, Hélène Sarter, Frédéric Gottrand, Colin Saoudi, Alexandre Louvet, Mathurin Fumery, Guillaume Savoye, Ariane Leroyer, Corinne Gower-Rousseau, Delphine Ley, Madeleine Aumar

Journal of Pediatric Gastroenterology and Nutrition · 2025-11 · 81 (5) · 1180-1188

DOI: 10.1002/jpn3.70176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 12.08.2025. Verfasst von Marie-Laura Godet und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology, Hepatology, and Nutrition Unit, Department of Pediatrics, CHU Lille, Lille, France. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: François Aupetit Association, Programme Hospitalier de Recherche Clinique interrégional, Conseil Régional du Nord-Pas-de-Calais (INSPIRED cohort).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess whether the prognosis of pediatric‐onset inflammatory bowel disease (IBD) is influenced by its association with primary sclerosing cholangitis (PSC) considering medical treatment, bowel resection, risk of cancer, and mortality.

Methods

A retrospective population‐based study was conducted using data from the EPIMAD Registry, one of the most extensive prospective population‐based IBD studies globally. Cases (IBD‐PSC) were compared with matched controls (matched‐IBD). Inclusion criteria were age ≤17 years at IBD diagnosis and follow‐up ≥2 years. PSC was confirmed by magnetic resonance cholangiopancreatography and/or histology. Each case was matched to four controls by propensity score (i.e., sex, age, year, and location of IBD at diagnosis).

Results

We included 24 cases and 96 controls. Median duration of follow‐up was 6.4 years (interquartile range = 3.1–14.3). No significant difference was observed between the two groups in terms of exposure to treatment at 5 years (immunosuppressants, corticosteroids, or antitumor necrosis factor). In IBD‐PSC, cancers were 28 times more frequent (standardized incidence ratio = 27.9; 95% confidence interval [CI], 7.0–111.7, p = 0.002), and death was 13 times more frequent (standardized mortality ratio = 13.3; 95% CI, 3.3–53.4, p = 0.010) than in the general population. No increased risk of cancer or mortality was observed in patients with IBD but without PSC compared to the general population.

Conclusion

Although the course of IBD is not different, the prognosis of pediatric‐onset IBD associated with PSC is significantly worse than that of pediatric‐onset IBD without PSC because of increased cancer and mortality rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingInflammatory Bowel DiseasesHumansMaleFemaleChildPrognosisRetrospective StudiesAdolescentCase-Control StudiesChild, PreschoolFollow-Up StudiesRegistriesIncidenceAge of Onset

Stichwörter der Autor:innen

Crohn's diseasecancerchildrenliver diseasemortalitytreatmentulcerative colitis

Autor:innen und Institutionen

  • Gastroenterology, Hepatology, and Nutrition Unit, Department of Pediatrics, CHU Lille, Lille, France.
  • U1286 - INFINITE - Institute for Translational Research in Inflammation, Univ. Lille, Inserm, CHU Lille, Lille, France.
  • Public Health, Epidemiology and Economic Health Unit, Epimad Registry, Maison Régionale de la Recherche Clinique, CHU Lille, Lille, France.
  • Division of Gastroenterology and Hepatology, Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
  • Gastroenterology Unit, Amiens University Hospital, and Peritox, UMRI01, Université de Picardie Jules Verne, Amiens, France.
  • Gastroenterology Unit, Rouen University Hospital, UMR 1073, University of Rouen Normandy, Rouen, France.

ORCID-Profile: Marie-Laura Godet

Förderung

  • François Aupetit Association
  • Programme Hospitalier de Recherche Clinique interrégional
  • Conseil Régional du Nord-Pas-de-Calais (INSPIRED cohort)
  • Lille University Hospital
  • Amiens University Hospital
  • Rouen University Hospital

Zitieren

APA

Godet, M. L., Sarter, H., Gottrand, F., Saoudi, C., Louvet, A., Fumery, M., Savoye, G., Leroyer, A., Gower-Rousseau, C., Ley, D., & Aumar, M. (2025). Prognosis of pediatric‐onset inflammatory bowel disease associated with primary sclerosing cholangitis: A population‐based study. Journal of Pediatric Gastroenterology and Nutrition, 81(5), 1180-1188. https://doi.org/10.1002/jpn3.70176

Vancouver

Godet ML, Sarter H, Gottrand F, Saoudi C, Louvet A, Fumery M, et al. Prognosis of pediatric‐onset inflammatory bowel disease associated with primary sclerosing cholangitis: A population‐based study. Journal of Pediatric Gastroenterology and Nutrition. 2025;81(5):1180-1188. doi:10.1002/jpn3.70176

BibTeX
@article{Godet2025,
  author = {Godet, Marie-Laura and Sarter, Hélène and Gottrand, Frédéric and Saoudi, Colin and Louvet, Alexandre and Fumery, Mathurin and Savoye, Guillaume and Leroyer, Ariane and Gower-Rousseau, Corinne and Ley, Delphine and Aumar, Madeleine},
  title = {Prognosis of pediatric‐onset inflammatory bowel disease associated with primary sclerosing cholangitis: A population‐based study},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2025},
  volume = {81},
  number = {5},
  pages = {1180--1188},
  doi = {10.1002/jpn3.70176}
}
Kostenlos starten →